The American College of Rheumatology presented a consensus document in 1999
proposing the classification of 19 different syndromes defined by neurological and …

Autoantibodies against β 2-glycoprotein I (β 2 GPI) appear to be a critical feature of the
antiphospholipid syndrome (APS). As determined using domain deletion mutants, human …

Introduction: Recent studies have identified circulating immunoglobulin (Ig) G
autoantibodies against cytoplasmic 5′‐nucleotidase 1A (cN1A; NT5C1A) in patients with …

There is increased scientific interest in the diagnosis of the antiphospholipid syndrome
(APS), as therapeutic interventions can lead to substantial improvement in clinical outcome …

The predictive value (PV) and association of 4 antiphospholipid antibodies with clinical
manifestations of the antiphospholipid syndrome (APS) were evaluated in 90 patients with …

This paper examines the methodology of anti-β2-glycoprotein I (β2-GPI) epitope
determination and provides further epitope studies using human sera containing anti-β2-GPI …

Condição adquirida, sistêmica, caracterizada por tromboses recorrentes no sistema arterial,
venoso ou ambos, a síndrome antifosfolípide pode ser primária ou secundária, esta última …

Antibodies against β2-glycoprotein I (anti-β2GPI) are one of the hallmarks of the
antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope …

The diagnosis of the antiphospholipid syndrome (APS) requires both a typical clinical event
plus a persistently positive test in an assay for either anticardiolipin (aCL) antibodies or a …

Lyso (bis) phosphatidic acid (LBPA) is a novel antigenic target in anti-phospholipid
syndrome (APS) and antibodies directed against LBPA (aLBPA) have been detected in sera …